A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor

Toru Fukuda, Kazuhiro Kanomata, Junya Nojima, Shoichiro Kokabu, Masumi Akita, Kenji Ikebuchi, Eijiro Jimi, Tetsuo Komori, Yuichi Maruki, Masaru Matsuoka, Kohei Miyazono, Konosuke Nakayama, Akira Nanba, Hiroshi Tomoda, Yasushi Okazaki, Akira Ohtake, Hiromi Oda, Ichiro Owan, Tetsuya Yoda, Nobuhiko HagaHirokazu Furuya, Takenobu Katagiri

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant congenital disorder characterized by progressive heterotopic bone formation in muscle tissues. A common mutation among FOP patients has been identified in ALK2, ALK2(R206H), which encodes a constitutively active bone morphogenetic protein (BMP) receptor. Recently, a unique mutation of ALK2, ALK2(G356D), was identified to be a novel mutation in a Japanese FOP patient who had unique clinical features. Over-expression of ALK2(G356D) induced phosphorylation of Smad1/5/8 and activated Id1-luc and alkaline phosphatase activity in myoblasts. However, the over-expression failed to activate phosphorylation of p38, ERK1/2, and CAGA-luc activity. These ALK2(G356D) activities were weaker than those of ALK2(R206H), and they were suppressed by a specific inhibitor of the BMP-regulated Smad pathway. These findings suggest that ALK2(G356D) induces heterotopic bone formation via activation of a BMP-regulated Smad pathway. The quantitative difference between ALK2(G356D) and ALK2(R206H) activities may have caused the phenotypic differences in these patients.

Original languageEnglish
Pages (from-to)905-909
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume377
Issue number3
DOIs
Publication statusPublished - Dec 19 2008

Fingerprint

Type I Bone Morphogenetic Protein Receptors
Myositis Ossificans
Bone Morphogenetic Proteins
Phosphorylation
Bone
Bone Morphogenetic Protein Receptors
Osteogenesis
Mutation
Alkaline Phosphatase
Muscle
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Myoblasts
Chemical activation
Tissue
Muscles

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. / Fukuda, Toru; Kanomata, Kazuhiro; Nojima, Junya; Kokabu, Shoichiro; Akita, Masumi; Ikebuchi, Kenji; Jimi, Eijiro; Komori, Tetsuo; Maruki, Yuichi; Matsuoka, Masaru; Miyazono, Kohei; Nakayama, Konosuke; Nanba, Akira; Tomoda, Hiroshi; Okazaki, Yasushi; Ohtake, Akira; Oda, Hiromi; Owan, Ichiro; Yoda, Tetsuya; Haga, Nobuhiko; Furuya, Hirokazu; Katagiri, Takenobu.

In: Biochemical and Biophysical Research Communications, Vol. 377, No. 3, 19.12.2008, p. 905-909.

Research output: Contribution to journalArticle

Fukuda, T, Kanomata, K, Nojima, J, Kokabu, S, Akita, M, Ikebuchi, K, Jimi, E, Komori, T, Maruki, Y, Matsuoka, M, Miyazono, K, Nakayama, K, Nanba, A, Tomoda, H, Okazaki, Y, Ohtake, A, Oda, H, Owan, I, Yoda, T, Haga, N, Furuya, H & Katagiri, T 2008, 'A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor', Biochemical and Biophysical Research Communications, vol. 377, no. 3, pp. 905-909. https://doi.org/10.1016/j.bbrc.2008.10.093
Fukuda, Toru ; Kanomata, Kazuhiro ; Nojima, Junya ; Kokabu, Shoichiro ; Akita, Masumi ; Ikebuchi, Kenji ; Jimi, Eijiro ; Komori, Tetsuo ; Maruki, Yuichi ; Matsuoka, Masaru ; Miyazono, Kohei ; Nakayama, Konosuke ; Nanba, Akira ; Tomoda, Hiroshi ; Okazaki, Yasushi ; Ohtake, Akira ; Oda, Hiromi ; Owan, Ichiro ; Yoda, Tetsuya ; Haga, Nobuhiko ; Furuya, Hirokazu ; Katagiri, Takenobu. / A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. In: Biochemical and Biophysical Research Communications. 2008 ; Vol. 377, No. 3. pp. 905-909.
@article{f35650cc297e4b2a87f9a23454a4b868,
title = "A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor",
abstract = "Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant congenital disorder characterized by progressive heterotopic bone formation in muscle tissues. A common mutation among FOP patients has been identified in ALK2, ALK2(R206H), which encodes a constitutively active bone morphogenetic protein (BMP) receptor. Recently, a unique mutation of ALK2, ALK2(G356D), was identified to be a novel mutation in a Japanese FOP patient who had unique clinical features. Over-expression of ALK2(G356D) induced phosphorylation of Smad1/5/8 and activated Id1-luc and alkaline phosphatase activity in myoblasts. However, the over-expression failed to activate phosphorylation of p38, ERK1/2, and CAGA-luc activity. These ALK2(G356D) activities were weaker than those of ALK2(R206H), and they were suppressed by a specific inhibitor of the BMP-regulated Smad pathway. These findings suggest that ALK2(G356D) induces heterotopic bone formation via activation of a BMP-regulated Smad pathway. The quantitative difference between ALK2(G356D) and ALK2(R206H) activities may have caused the phenotypic differences in these patients.",
author = "Toru Fukuda and Kazuhiro Kanomata and Junya Nojima and Shoichiro Kokabu and Masumi Akita and Kenji Ikebuchi and Eijiro Jimi and Tetsuo Komori and Yuichi Maruki and Masaru Matsuoka and Kohei Miyazono and Konosuke Nakayama and Akira Nanba and Hiroshi Tomoda and Yasushi Okazaki and Akira Ohtake and Hiromi Oda and Ichiro Owan and Tetsuya Yoda and Nobuhiko Haga and Hirokazu Furuya and Takenobu Katagiri",
year = "2008",
month = "12",
day = "19",
doi = "10.1016/j.bbrc.2008.10.093",
language = "English",
volume = "377",
pages = "905--909",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor

AU - Fukuda, Toru

AU - Kanomata, Kazuhiro

AU - Nojima, Junya

AU - Kokabu, Shoichiro

AU - Akita, Masumi

AU - Ikebuchi, Kenji

AU - Jimi, Eijiro

AU - Komori, Tetsuo

AU - Maruki, Yuichi

AU - Matsuoka, Masaru

AU - Miyazono, Kohei

AU - Nakayama, Konosuke

AU - Nanba, Akira

AU - Tomoda, Hiroshi

AU - Okazaki, Yasushi

AU - Ohtake, Akira

AU - Oda, Hiromi

AU - Owan, Ichiro

AU - Yoda, Tetsuya

AU - Haga, Nobuhiko

AU - Furuya, Hirokazu

AU - Katagiri, Takenobu

PY - 2008/12/19

Y1 - 2008/12/19

N2 - Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant congenital disorder characterized by progressive heterotopic bone formation in muscle tissues. A common mutation among FOP patients has been identified in ALK2, ALK2(R206H), which encodes a constitutively active bone morphogenetic protein (BMP) receptor. Recently, a unique mutation of ALK2, ALK2(G356D), was identified to be a novel mutation in a Japanese FOP patient who had unique clinical features. Over-expression of ALK2(G356D) induced phosphorylation of Smad1/5/8 and activated Id1-luc and alkaline phosphatase activity in myoblasts. However, the over-expression failed to activate phosphorylation of p38, ERK1/2, and CAGA-luc activity. These ALK2(G356D) activities were weaker than those of ALK2(R206H), and they were suppressed by a specific inhibitor of the BMP-regulated Smad pathway. These findings suggest that ALK2(G356D) induces heterotopic bone formation via activation of a BMP-regulated Smad pathway. The quantitative difference between ALK2(G356D) and ALK2(R206H) activities may have caused the phenotypic differences in these patients.

AB - Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant congenital disorder characterized by progressive heterotopic bone formation in muscle tissues. A common mutation among FOP patients has been identified in ALK2, ALK2(R206H), which encodes a constitutively active bone morphogenetic protein (BMP) receptor. Recently, a unique mutation of ALK2, ALK2(G356D), was identified to be a novel mutation in a Japanese FOP patient who had unique clinical features. Over-expression of ALK2(G356D) induced phosphorylation of Smad1/5/8 and activated Id1-luc and alkaline phosphatase activity in myoblasts. However, the over-expression failed to activate phosphorylation of p38, ERK1/2, and CAGA-luc activity. These ALK2(G356D) activities were weaker than those of ALK2(R206H), and they were suppressed by a specific inhibitor of the BMP-regulated Smad pathway. These findings suggest that ALK2(G356D) induces heterotopic bone formation via activation of a BMP-regulated Smad pathway. The quantitative difference between ALK2(G356D) and ALK2(R206H) activities may have caused the phenotypic differences in these patients.

UR - http://www.scopus.com/inward/record.url?scp=56049098488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049098488&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2008.10.093

DO - 10.1016/j.bbrc.2008.10.093

M3 - Article

C2 - 18952055

AN - SCOPUS:56049098488

VL - 377

SP - 905

EP - 909

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -